Pyrotinib Maleate
Phase 3Small molecule
AstraZenecaPyrotinib Maleate is one of 128 small molecule programs targeting Non-Small Cell Lung Cancer. It is currently in Phase 3.
4
Indications
17
Total Trials
5
Active Trials
127
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
744 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Pyrotinib Maleate
AstraZenecaPhase 3
Blenoxane
Bristol-Myers SquibbPreclinical
Neoadjuvant Treatment
SShanghai Zhongshan Hospital
Preclinical
Tianeptine
PfizerPreclinical
Recombinant Human Endostatin
PPeking University Third Hospital
Preclinical
Metfomin
UUniversity of Texas Southwestern Medical Center
Preclinical
Bisphosphonate
AmgenPreclinical
Naltrexone/bupropion
Novo NordiskPreclinical
Perflutren Lipid Microsphere
IImaRx Therapeutics
Preclinical
Sertraline ODT
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Breast Cancer10 trials
Show 7 more trials
Interaction2 trials
Brain Metastases1 trial
Non-Small Cell Lung Cancer1 trial
A Real-World Study of Pyrotinib Maleate in the Treatment of Advanced/Metastatic Non-Small Cell Lung Cancer With Rare Mutations in HER2
Unknown status·—··NCT05411276·15 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Pyrotinib Maleate. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company